@article{JTD4148,
author = {Nevin Murray},
title = {The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {7},
number = {3},
year = {2015},
keywords = {},
abstract = {The discovery of treatable molecular targets in the adenocarcinoma histologic subtype of non-small cell lung cancer (NSCLC) with approved drugs is the most conspicuous and exciting development in the treatment of advanced lung cancer (1,2). No molecular targets treatable with drugs with proven efficacy have been described for squamous or small cell lung cancer (3). However, in adenocarcinomas, a number of mutations and gene fusions have been identified that drive cancer growth. These oncogenic targets guide treatment selection for specific patient subsets and the concept of “personalized therapy” has transformed the standard of care. There are four key components of personalized therapy. The first is the presence of an oncogenic target that drives cancer growth. Second is a predictive biomarker that detects the presence of the target. The third component is a drug that blocks the driver mutation with manageable normal tissue toxicity.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/4148}
}